Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 5/20 | 0.34 |
| ▸ | CDK5R1 | Q15078 | 5/20 | 0.34 |
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22718265 | 0.94 | CPB2 (0.34) | CDK5CDK5R1CPB2 | |
| SCHEMBL31591382 | 0.84 | — | — | |
| SCHEMBL30990437 | 0.78 | GPR119 (0.42) | — | |
| SCHEMBL2378967 | 0.73 | PHF8 (0.37) | — | |
| SCHEMBL251041 | 0.73 | CYP2C9 (0.35) | — | |
| SCHEMBL31308740 | 0.71 | CYP2E1 (0.35) | — | |
| SCHEMBL14699051 | 0.70 | CYP2C9 (0.33) | — | |
| SCHEMBL18344826 | 0.70 | KDM5A (0.35) | CPB2 | |
| SCHEMBL22747428 | 0.69 | CPB2 (0.43) | CDK5CDK5R1CPB2 | |
| SCHEMBL15266297 | 0.69 | CCNB2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124197-A1 | NOVEL HETEROBICYCLIC COMPOUND FOR INHIBITING YAP-TEAD INTERACTION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | HANMI PHARMACEUTICAL CO LTD (KR) | 2026-05-07 | — | — | US | disclosed |
| US-12577208-B2 | TEAD inhibitors and uses thereof | EHE Foundation (US) | 2026-03-17 | — | — | US | disclosed |
| US-20250353831-A1 | NOVEL HETEROBICYCLIC COMPOUND FOR INHIBITING YAP-TEAD INTERACTION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | HANMI PHARMACEUTICAL CO LTD (KR) | 2025-11-20 | — | — | US | disclosed |
| EP-4581027-A1 | NOVEL HETEROBICYCLIC COMPOUND FOR INHIBITING YAP-TEAD INTERACTION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Hanmi Pharm. Co., Ltd. (KR) | 2025-07-09 | — | — | EP | disclosed |
| EP-4581026-A1 | NOVEL HETEROBICYCLIC COMPOUND FOR INHIBITING YAP-TEAD INTERACTION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Hanmi Pharm. Co., Ltd. (KR) | 2025-07-09 | — | — | EP | disclosed |
| CN-120051465-A | Novel heterobicyclic compounds for inhibiting YAP-TEAD interactions and pharmaceutical compositions containing the same | 韩美药品株式会社 | 2025-05-27 | — | — | CN | disclosed |
| CN-120019051-A | Novel heterobicyclic compounds for inhibiting YAP-TEAD interactions and pharmaceutical compositions containing the same | 韩美药品株式会社 | 2025-05-16 | — | — | CN | disclosed |
| CN-119954725-A | TEAD inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-114466839-B | TEAD inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2025-01-07 | — | — | CN | disclosed |
| WO-2024080792-A1 | NOVEL HETEROBICYCLIC COMPOUND FOR INHIBITING YAP-TEAD INTERACTION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | HANMI PHARM. CO., LTD. (KR) | 2024-04-18 | — | — | WO | disclosed |
| WO-2024080793-A1 | NOVEL HETEROBICYCLIC COMPOUND FOR INHIBITING YAP-TEAD INTERACTION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | HANMI PHARM. CO., LTD. (KR) | 2024-04-18 | — | — | WO | disclosed |
| US-20240083854-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2024-03-14 | — | — | US | disclosed |
| US-11760728-B2 | Tead inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20220251048-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2022-08-11 | — | — | US | disclosed |
| CN-114466839-A | TEAD inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2022-05-10 | — | — | CN | disclosed |
| EP-3976194-A2 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| US-11274082-B2 | Tead inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2022-03-15 | — | — | US | disclosed |
| US-20200407327-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2020-12-31 | — | — | US | disclosed |
| WO-2020243415-A2 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2020-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251048-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | CDK5 301/4885CDK5R1 929/4885CPB2 2318/4885 |
| US-20250353831-A1 | NOVEL HETEROBICYCLIC COMPOUND FOR INHIBITING YAP-TEAD INTERACTION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | YAP1, TEAD2, TEAD1 | CDK5 857/4885CDK5R1 1122/4885CPB2 4180/4885 |
| US-11274082-B2 | Tead inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | CDK5 301/4885CDK5R1 929/4885CPB2 2318/4885 |
| US-20260124197-A1 | NOVEL HETEROBICYCLIC COMPOUND FOR INHIBITING YAP-TEAD INTERACTION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | YAP1, RCC1, YES1 | CDK5 1324/4885CDK5R1 1151/4885CPB2 3903/4885 |
| US-20240083854-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | CDK5 301/4885CDK5R1 929/4885CPB2 2318/4885 |
| US-11760728-B2 | Tead inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | CDK5 301/4885CDK5R1 929/4885CPB2 2318/4885 |
| US-12577208-B2 | TEAD inhibitors and uses thereof | BRCA1, BRAF, MEN1 | CDK5 2566/4885CDK5R1 2810/4885CPB2 3321/4885 |
| US-20200407327-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | CDK5 301/4885CDK5R1 929/4885CPB2 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.